The purpose of the test is to:
The Double Marker Test is a prenatal blood screening test performed during early pregnancy to assess the likelihood of certain chromosomal abnormalities in the developing baby. It typically measures two biochemical markers in the mother's blood: free beta-hCG and PAPP-A (Pregnancy-Associated Plasma Protein-A).
The results are usually combined with factors such as maternal age and ultrasound findings, particularly the nuchal translucency (NT) measurement, to calculate an individualized risk estimate for chromosomal conditions such as Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13).
The Double Marker Test is a screening test, not a diagnostic test. A high-risk result does not confirm that the baby has a chromosomal abnormality. Your healthcare provider may recommend further evaluation, such as NIPT or diagnostic testing like chorionic villus sampling (CVS) or amniocentesis, depending on the overall risk assessment.
1. What does the Double Marker Test check?
It measures free beta-hCG and PAPP-A in maternal blood and combines the results with other factors to estimate the risk of certain chromosomal abnormalities.
2. When is the Double Marker Test performed?
It is generally performed during the first trimester, commonly around 11 to 13+6 weeks of pregnancy, depending on the screening protocol and healthcare provider's recommendation.
3. Does a high-risk Double Marker result mean the baby has Down syndrome?
No. The Double Marker Test is a screening test, so a high-risk result only indicates an increased probability. Additional screening or diagnostic testing may be recommended to determine the actual risk more accurately.